Schrödinger Appoints Dov Goldstein, M.D., as Chief Financial Officer

"We are thrilled to welcome Dov to our leadership team as he brings significant depth of financial experience and a proven track record of successfully spearheading and guiding financial strategy at private and public healthcare companies," said Ramy Farid, Ph.D., President and Chief Executive Officer. "We look forward to his leadership and contribution in this exciting period of growth for Schrödinger as we look to further develop and commercialize our leading computational chemistry platform, as well as found new companies and collaborations to spur drug discovery enhanced by the platform."

"I have worked with innovative healthcare companies for many years, both internally as a CFO and externally as an investor, and I am extremely impressed by Schrödinger's revolutionary drug discovery platform and business," said Dov Goldstein, M.D. "I'm very excited to join this dynamic team, and look forward to helping to drive future growth and value for the Company."

Before Aisling Capital, Dr. Goldstein was Executive Vice President, Finance and Chief Financial Officer at Vicuron Pharmaceuticals, where he raised over $250 million in equity financings and managed investor relations, press relations, and financial operations for the company. He also served as Chief Financial Officer at Loxo Oncology. Previously, Dr. Goldstein was Director of Venture Analysis at Healthcare Ventures, where he led due diligence for new investments and business development for portfolio companies. Prior to joining the financial industry, he completed his internal medicine internship at Columbia Presbyterian Hospital. Dr. Goldstein holds an M.B.A from Columbia Business School, an M.D. from Yale University School of Medicine, and a B.S. in Biological Sciences from Stanford University.

About Schrödinger

Schrödinger is a leading provider of advanced molecular simulations and enterprise software solutions and services to accelerate and increase the efficiency of drug discovery for its clients, which include all major pharmaceutical and biotechnology companies worldwide, as well as leading materials science researchers. Schrödinger also establishes deep partnerships and collaborations with companies in such fields as biotechnology, pharmaceuticals, chemicals, and electronics, and was a cofounder of leading biotech companies including Nimbus Therapeutics, Morphic Therapeutic, and others. Schrödinger's investors include David E. Shaw and Bill Gates. Through significant long-term investments in basic research, Schrödinger has made scientific breakthroughs across many areas of drug discovery and materials science. Hundreds of peer-reviewed scientific publications by Schrödinger scientists are frequently among the most heavily cited in their fields. Founded in 1990, Schrödinger has over 300 employees and operations in the United States, Europe, Japan, and India, as well as business partners in China and Korea. For more information, please visit www.schrodinger.com.

SOURCE Schrödinger

Related Links

http://www.schrodinger.com